aspartic acid has been researched along with Melanoma in 37 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 9.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Twenty-two patients with advanced malignant melanoma were entered in a pilot study receiving combination chemotherapy with PALA, vindesine, and cisplatin (PVP)." | 7.67 | PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study. ( Kleeberg, UR; Voigt, H, 1984) |
| " In the human melanoma cell lines IGR3 and M5 the main metabolite of 5FU was 5-fluorouridine, while in the murine B16 melanoma only a small amount of 5-fluorouridine was formed." | 7.67 | Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. ( Lankelma, J; Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM, 1984) |
| "We conducted parallel phase II trials of cimetidine as a single agent and the combination N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine among 40 previously untreated patients with biopsy-proven, measurable disseminated malignant melanoma." | 5.06 | Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma. ( Chang, M; Creagan, ET; Cullinan, SA; Ebbert, L; Mailliard, JA; Morton, RF; Veeder, MH, 1987) |
| "Twenty-two patients with advanced malignant melanoma were entered in a pilot study receiving combination chemotherapy with PALA, vindesine, and cisplatin (PVP)." | 3.67 | PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study. ( Kleeberg, UR; Voigt, H, 1984) |
| " To test this hypothesis we examined the effects of PALA and nitrobenzylthioinosine (NBMPR) alone and in combination on B16 melanoma cells in vitro using a clonogenic assay and in vivo using growth delay." | 3.67 | Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine. ( Erlichman, C; Vidgen, D, 1984) |
| " In the human melanoma cell lines IGR3 and M5 the main metabolite of 5FU was 5-fluorouridine, while in the murine B16 melanoma only a small amount of 5-fluorouridine was formed." | 3.67 | Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars. ( Lankelma, J; Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM, 1984) |
| "Six CDKN2A families had pancreatic cancer." | 1.31 | Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. ( Chidambaram, A; Fraser, MC; Goldstein, AM; Struewing, JP; Tucker, MA, 2000) |
| "Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma." | 1.31 | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001) |
| "Another solid tumor, Ridgway osteogenic sarcoma, which is sensitivie to many established chemotherapeutic agents, did not respond to PALA." | 1.26 | Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase. ( Goldin, A; Inouye, T; Johnson, RK; Stark, GR, 1976) |
| "It was found that SV40-induced hamster tumors, BHK21/cl 13 cells in culture, certain carcinogen-induced tumors in the Ehrlich ascites tumor, and a number of human carcinomas and adenocarcinomas contained a distinct increase (3- to 20-fold) in the percentage of a late-eluting aspartyl-tRNA over that found in nonmalignant tissues, other animal tumors, and in human melanomas and sarcomas." | 1.25 | The distribution and properties of aspartyl transfer RNA in human and animal tumors. ( Bowen, JM; Briscoe, WT; Griffin, AC; McBride, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (45.95) | 18.7374 |
| 1990's | 5 (13.51) | 18.2507 |
| 2000's | 7 (18.92) | 29.6817 |
| 2010's | 5 (13.51) | 24.3611 |
| 2020's | 3 (8.11) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, Z | 1 |
| Wang, H | 1 |
| Chen, Z | 1 |
| Dong, X | 1 |
| Zhao, W | 1 |
| Shi, Y | 1 |
| Zhu, Q | 1 |
| Novak, P | 3 |
| Balakin, A | 3 |
| Temnik, M | 3 |
| Sun, S | 1 |
| Deng, M | 1 |
| Wen, J | 1 |
| Chen, X | 1 |
| Xu, J | 1 |
| Liu, Y | 1 |
| Wan, H | 1 |
| Wang, J | 1 |
| Yan, L | 1 |
| He, Y | 1 |
| Xu, Y | 1 |
| Pathria, G | 2 |
| Scott, DA | 1 |
| Feng, Y | 1 |
| Sang Lee, J | 1 |
| Fujita, Y | 1 |
| Zhang, G | 1 |
| Sahu, AD | 1 |
| Ruppin, E | 1 |
| Herlyn, M | 1 |
| Osterman, AL | 1 |
| Ronai, ZA | 1 |
| Rinck-Junior, JA | 1 |
| Torricelli, C | 1 |
| Gomez, GVB | 1 |
| Oliveira, C | 1 |
| Moraes, AM | 1 |
| Lourenço, GJ | 1 |
| Lima, CSP | 1 |
| Ramos, CJ | 1 |
| Gutierrez, DA | 1 |
| Aranda, AS | 1 |
| Koshlaychuk, MA | 1 |
| Carrillo, DA | 1 |
| Medrano, R | 1 |
| McBride, TD | 1 |
| U, A | 1 |
| Medina, SM | 1 |
| Lombardo, MC | 1 |
| Lucena, SE | 1 |
| Sanchez, EE | 1 |
| Soto, JG | 1 |
| Jalili, A | 1 |
| Wagner, C | 1 |
| Pashenkov, M | 1 |
| Mertz, KD | 1 |
| Widlund, HR | 1 |
| Lupien, M | 1 |
| Brunet, JP | 1 |
| Golub, TR | 1 |
| Stingl, G | 1 |
| Fisher, DE | 1 |
| Ramaswamy, S | 1 |
| Wagner, SN | 1 |
| Leonhardt, RM | 1 |
| Vigneron, N | 1 |
| Hee, JS | 1 |
| Graham, M | 1 |
| Cresswell, P | 1 |
| Wolchok, JD | 1 |
| Chapman, PB | 1 |
| Lauer-Fields, JL | 1 |
| Malkar, NB | 1 |
| Richet, G | 1 |
| Drauz, K | 1 |
| Fields, GB | 1 |
| Shonukan, O | 1 |
| Bagayogo, I | 1 |
| McCrea, P | 1 |
| Chao, M | 1 |
| Hempstead, B | 1 |
| Peters, GJ | 2 |
| Laurensse, E | 2 |
| Leyva, A | 3 |
| Pinedo, HM | 3 |
| Kleeberg, UR | 2 |
| Mulder, JH | 1 |
| Rümke, P | 1 |
| Thomas, D | 1 |
| Rozencweig, M | 1 |
| Voigt, H | 1 |
| Erlichman, C | 3 |
| Vidgen, D | 1 |
| Lankelma, J | 2 |
| Donehower, RC | 1 |
| Speyer, JL | 1 |
| Klecker, R | 1 |
| Chabner, BA | 1 |
| Appel, H | 1 |
| Smith, P | 1 |
| Karle, JM | 1 |
| Anderson, LW | 1 |
| Cysyk, RL | 1 |
| Skipper, JC | 1 |
| Hendrickson, RC | 1 |
| Gulden, PH | 1 |
| Brichard, V | 1 |
| Van Pel, A | 1 |
| Chen, Y | 1 |
| Shabanowitz, J | 1 |
| Wolfel, T | 1 |
| Slingluff, CL | 1 |
| Boon, T | 1 |
| Hunt, DF | 1 |
| Engelhard, VH | 1 |
| Cleaveland, ES | 1 |
| Zaharevitz, DW | 1 |
| Kelley, JA | 1 |
| Paull, K | 1 |
| Cooney, DA | 1 |
| Ford, H | 1 |
| Valverde, P | 1 |
| Healy, E | 1 |
| Sikkink, S | 1 |
| Haldane, F | 1 |
| Thody, AJ | 1 |
| Carothers, A | 1 |
| Jackson, IJ | 1 |
| Rees, JL | 1 |
| Goldstein, AM | 1 |
| Struewing, JP | 1 |
| Chidambaram, A | 1 |
| Fraser, MC | 1 |
| Tucker, MA | 1 |
| Ruediger, R | 1 |
| Pham, HT | 1 |
| Walter, G | 1 |
| D'Angelo, S | 1 |
| Ingrosso, D | 1 |
| Perfetto, B | 1 |
| Baroni, A | 1 |
| Zappia, M | 1 |
| Lobianco, LL | 1 |
| Tufano, MA | 1 |
| Galletti, P | 1 |
| Zhang, B | 1 |
| Peng, ZY | 1 |
| Briscoe, WT | 1 |
| Griffin, AC | 1 |
| McBride, C | 1 |
| Bowen, JM | 1 |
| Johnson, RK | 2 |
| Swyryd, EA | 1 |
| Stark, GR | 3 |
| Inouye, T | 1 |
| Goldin, A | 1 |
| Komoriya, A | 1 |
| Green, LJ | 1 |
| Mervic, M | 1 |
| Yamada, SS | 1 |
| Yamada, KM | 1 |
| Humphries, MJ | 1 |
| McMillan, TJ | 1 |
| Kalebic, T | 1 |
| Hart, IR | 1 |
| Cillo, C | 1 |
| Dick, JE | 1 |
| Ling, V | 1 |
| Hill, RP | 1 |
| Morton, RF | 1 |
| Creagan, ET | 1 |
| Cullinan, SA | 1 |
| Mailliard, JA | 1 |
| Ebbert, L | 1 |
| Veeder, MH | 1 |
| Chang, M | 1 |
| Chan, TC | 1 |
| Young, B | 1 |
| King, ME | 1 |
| Taetle, R | 1 |
| Howell, SB | 1 |
| Hoffer, PB | 1 |
| Gottschalk, A | 1 |
| Ohnuma, T | 1 |
| Holland, JF | 1 |
| Freeman, A | 1 |
| Sinks, LF | 1 |
| Hempel, K | 1 |
| Männl, HF | 1 |
1 review available for aspartic acid and Melanoma
| Article | Year |
|---|---|
Tumor scanning agents.
Topics: Antibodies, Neoplasm; Aspartic Acid; Bismuth; Bleomycin; Carbon Radioisotopes; Carcinoembryonic Anti | 1974 |
1 trial available for aspartic acid and Melanoma
| Article | Year |
|---|---|
Phase II studies of single-agent cimetidine and the combination N-phosphonacetyl-L-aspartate (NSC-224131) plus L-alanosine (NSC-153353) in advanced malignant melanoma.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cimetidine; Drug Evaluation; | 1987 |
35 other studies available for aspartic acid and Melanoma
| Article | Year |
|---|---|
Discovery of an Amino Acid-Modified Near-Infrared Aza-BODIPY Photosensitizer as an Immune Initiator for Potent Photodynamic Therapy in Melanoma.
Topics: Amino Acids; Animals; Aspartic Acid; Boron Compounds; Cell Line, Tumor; Drug Discovery; Female; Huma | 2022 |
Topics: Aspartic Acid; Glutamic Acid; Humans; Isotopes; Melanoma; Zinc; Zinc Isotopes | 2022 |
Topics: Aspartic Acid; Glutamic Acid; Humans; Isotopes; Melanoma; Zinc; Zinc Isotopes | 2022 |
Topics: Aspartic Acid; Glutamic Acid; Humans; Isotopes; Melanoma; Zinc; Zinc Isotopes | 2022 |
Topics: Aspartic Acid; Glutamic Acid; Humans; Isotopes; Melanoma; Zinc; Zinc Isotopes | 2022 |
Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma.
Topics: Aspartic Acid; B7 Antigens; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mixed Function Oxygenas | 2023 |
Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival.
Topics: Activating Transcription Factor 4; Amino Acid Transport System ASC; Aspartic Acid; Cell Line, Tumor; | 2018 |
Influence of functional variants Asp312Asn and Lys751Gln of Xeroderma Pigmentosum Group D (XPD) and Glutathione S-transferase Mu 1 (GSTM1) and Theta 1 (GSTT1) genes on cutaneous melanoma susceptibility and prognosis.
Topics: Aged; Asparagine; Aspartic Acid; Cell Survival; Disease-Free Survival; Genetic Predisposition to Dis | 2019 |
Functional characterization of six aspartate (D) recombinant mojastin mutants (r-Moj): A second aspartate amino acid carboxyl to the RGD in r-Moj-D_ peptides is not sufficient to induce apoptosis of SK-Mel-28 cells.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Apoptosis; Aspartic Acid; Cell Line, Tumor; Cell | 2016 |
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Blotting, Western; Cell Line, Tumor; Cycl | 2012 |
Critical residues in the PMEL/Pmel17 N-terminus direct the hierarchical assembly of melanosomal fibrils.
Topics: Amino Acid Sequence; Amyloid; Aspartic Acid; Binding Sites; Blotting, Western; Cell Line, Tumor; gp1 | 2013 |
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope.
Topics: Asparagine; Aspartic Acid; Clinical Trials, Phase I as Topic; Codon; Deamination; Epitopes, T-Lympho | 2002 |
Melanoma cell CD44 interaction with the alpha 1(IV)1263-1277 region from basement membrane collagen is modulated by ligand glycosylation.
Topics: Amino Acids; Aspartic Acid; Binding Sites; Carbazoles; Cell Adhesion; Chondroitin Sulfate Proteoglyc | 2003 |
Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin.
Topics: Actins; Amino Acid Substitution; Aspartic Acid; Carrier Proteins; Cell Movement; Cytoskeleton; Human | 2003 |
Fluctuations in phosphoribosyl pyrophosphate levels in monolayer tumor cell lines. Effects of drugs.
Topics: Animals; Aspartic Acid; Buffers; Cell Line; Cytological Techniques; Fibroblasts; Humans; Melanoma; M | 1984 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Drug Eruptions; Drug Evaluation; Female; Humans; | 1982 |
PALA, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma. A pilot study.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bone Marrow; C | 1984 |
Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1984 |
Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars.
Topics: Animals; Aspartic Acid; Cell Line; Cells, Cultured; Chromatography; Deoxyuracil Nucleotides; Fluorod | 1984 |
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1982 |
Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Cell Division; Cell L | 1981 |
Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Colonic Neoplasms; Drug Evaluation; Humans; Melanoma | 1980 |
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.
Topics: Amino Acid Sequence; Antigens, Neoplasm; Asparagine; Aspartic Acid; Clone Cells; Epitopes; HLA-A2 An | 1996 |
Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Topics: Antineoplastic Agents; Aspartic Acid; Biphenyl Compounds; Breast Neoplasms; Carbolines; Carcinoma, N | 1996 |
The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma.
Topics: Alleles; Aspartic Acid; Gene Frequency; Genetic Predisposition to Disease; Humans; Melanoma; Point M | 1996 |
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Arginine; Aspartic Acid; Cyclin-Dependent Kinases; Cysteine; G | 2000 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma | 2001 |
UVA irradiation induces L-isoaspartyl formation in melanoma cell proteins.
Topics: Animals; Aspartic Acid; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Humans; Melanoma; Neoplasm Pro | 2001 |
Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Topics: Ankyrin Repeat; Aspartic Acid; Circular Dichroism; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinas | 2002 |
The distribution and properties of aspartyl transfer RNA in human and animal tumors.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Carcinoma; Carcinoma, Ehrlich Tumor; Cells, Cultured; Cricet | 1975 |
Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Topics: Animals; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Cells, Cult | 1978 |
Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Topics: Animals; Antineoplastic Agents; Aspartate Carbamoyltransferase; Aspartic Acid; Carbamyl Phosphate; D | 1976 |
The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine.
Topics: Amino Acid Sequence; Animals; Aspartic Acid; Cattle; Cell Adhesion; Chickens; Fibronectins; Humans; | 1991 |
High frequency of double drug resistance in the B16 melanoma cell line.
Topics: Amides; Animals; Antineoplastic Agents; Aspartic Acid; Cell Line; Colony-Forming Units Assay; Drug R | 1990 |
Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
Topics: Animals; Aspartic Acid; Cell Line; Drug Resistance; Gene Amplification; Mathematics; Melanoma; Metho | 1987 |
Modulation of the activity of PALA by dipyridamole.
Topics: Animals; Aspartic Acid; Biological Transport; Cell Line; Colonic Neoplasms; Dipyridamole; Drug Inter | 1985 |
Biochemical and pharmacological studies with asparaginase in man.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Colo | 1970 |
The conversion of [3H]tyrosine to [3H]DOPA in mouse melanoma in vivo.
Topics: Animals; Asparagine; Aspartic Acid; Chromatography, Paper; Dihydroxyphenylalanine; Electrophoresis; | 1966 |